论文部分内容阅读
本文应用流式细胞仪（ＦＣＭ）分析了２３例不同临床期多发性骨髓瘤（ＭＭ）患者Ｔ细胞亚群、ＮＫ细胞及ＣＤ１９＋Ｂ淋巴细胞变化。结果显示：初诊未化疗ＭＭ患者ＣＤ４、ＣＤ２５、ＣＤ１９细胞百分率ＣＤ４／ＣＤ８比值均下降，ＣＤ８细胞百分率升高；稳定期ＭＭ患者除ＣＤ２５、ＣＤ１９细胞百分率下降外，其他指标均正常；进展期ＭＭ患者ＣＤ３、ＣＤ４细胞百分率和ＣＤ４／ＣＤ８比值下降，ＣＤ８、ＣＤ１９细胞百分率升高；不同临床期ＭＭ患者ＮＫ细胞与正常人比较无显著差异（Ｐ＞０．０５）。研究结果表明：不同临床期ＭＭ患者细胞免疫功能不同，细胞免疫调节异常在ＭＭ发病机制及稳定期脱逸过程中可能起一定作用。
In this study, flow cytometry (FCM) was used to analyze the changes of T cell subsets, NK cells and CD19+ B lymphocytes in 23 patients with multiple myeloma (MM) at different clinical stages. The results showed that the percentage of CD4, CD25, and CD19 cells and the percentage of CD8 cells in newly diagnosed non-chemotherapy MM patients were all decreased, and the percentage of CD8 cells was increased. In stable MM patients, except that the percentage of CD25 and CD19 cells was decreased, other indicators were normal; The percentages of CD3 and CD4 cells and the ratio of CD4/CD8 decreased, and the percentage of CD8 and CD19 cells increased. There was no significant difference between normal NK cells and NK cells in different clinical stages (P>0.05). The results of the study indicate that different cellular immune functions are different in patients with MM in different clinical stages, and abnormal cellular immune regulation may play a role in the pathogenesis of MM and the escape of stable phase.